Abstract
Human pluripotent stem cells (PSCs), which include human embryonic stem cells (ESCs) as well as induced pluripotent stem cells (iPSCs), represent an important source of cellular therapies in regenerative medicine and the study of early human development. As such, it is becoming increasingly important to develop methods for the large-scale banking of human PSC lines. There are several well-established methods for the propagation of human PSCs. The key to development of a good manufacturing practice (GMP) bank is to determine a manufacturing method that is amenable to large-scale production using materials that are fully documented. We have developed several banks of hESCs using animal feeder cells, animal-based matrices, or animal-free matrices. Protocols for growing hESCs on mouse embryonic fibroblasts (MEFs) are well established and are very helpful for producing research grade banks of cells. As most human ESCs cultured by research laboratories have been exposed to xenogeneic reagents, it is not imperative that all materials used in the production of a master cell bank be animal-free in origin. Nevertheless, as the field develops, it will no doubt become increasingly important to produce a bank of cells for clinical use without xenogeneic reagents, particularly nonhuman feeder cells which might harbor viruses with potential risk to human health or cell product integrity. Thus, even for cell lines previously exposed to xenogeneic reagents, it is important to minimize any subsequent exposure of the cell lines to additional adventitious agents. We have specifically described procedures for the growth of hESCs on Matrigel, an animal-matrix, and CELLstart, an animal-free matrix, and these can be used to produce hESCs as part of a clinical manufacturing process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998) Embryonic stem cell lines derived from human blastocysts, Science 282, 1145–1147.
Crook, J. M., Peura, T. T., Kravets, L., Bosman, A. G., Buzzard, J. J., Horne, R., Hentze, H., Dunn, N. R., Zweigerdt, R., Chua, F., Upshall, A., and Colman, A. (2007) The generation of six clinical-grade human embryonic stem cell lines, Cell Stem Cell 1, 490–4.
Carpenter, M. K., Frey-Vasconcells, J., and Rao, M. S. (2009) Developing safe therapies from human pluripotent stem cells, Nat Biotechnol 27, 606–613.
FDA, Guidance for Industry (2009) Current good tissue practice (CGTP) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-based products (HCT/Ps).
FDA, Guidance for FDA reviewers and sponsors (2008) Content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs).
Loring, J. F. and Rao, M. S. (2006) Establishing standards for the characterization of human embryonic stem cell lines, Stem Cells 24, 145–150.
The international Stem Cell Initiative (2007) Characterization of human embryonic stem cell lines by the International Stem Cell Initiative, Nat Biotech 25, 803–816.
Gonzalez, R., Loring, J. F., Snyder, E. Y. (2008) Preparation of autogenic human feeder cells for growth of human embryonic stem cells in, Current Protocols in Stem Cell Biology 4, 1 C.5.1-1 C.5.15.
Amit, M., and Itskovitz-Eldor, J. (2006) Feeder-free culture of human embryonic stem cells in, Methods in Enzymology 420, 37–49.
Xu, C., Inokuma, M. S., Denham, J., Golds, K., Kundu, P., Gold, J. D., and Carpenter, M. K. (2001) Feeder-free growth of undifferentiated human embryonic stem cells, Nat Biotechnol 19, 971–974.
Swistowski, A., Peng, J., Han, Y., Swistowska, A. M., Rao, M. S., and Zeng, X. (2009) Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them, PLoS One 4, 6233.
Acknowledgments
The authors would like to thank David Hsu for scientific advice, and Sylvana Couture and Christine Knoblauch for technical assistance. This work was supported by City of Hope and a grant from the California Institute of Regenerative Medicine (CIRM).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ausubel, L.J., Lopez, P.M., Couture, L.A. (2011). GMP Scale-Up and Banking of Pluripotent Stem Cells for Cellular Therapy Applications. In: Schwartz, P., Wesselschmidt, R. (eds) Human Pluripotent Stem Cells. Methods in Molecular Biology, vol 767. Humana Press. https://doi.org/10.1007/978-1-61779-201-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-61779-201-4_11
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-200-7
Online ISBN: 978-1-61779-201-4
eBook Packages: Springer Protocols